Critical analysis of diagnostic criteria (ICHD-3 beta) about migraine in childhood and adolescence

Abstract

Objective The objective of this study was to prospectively evaluate the International Classification of Headache Disorders I (ICHD-I) diagnostic criteria for migraine in children and adolescents. Methods 150 pain diaries were analyzed during an initial consultation. The duration of migraine headache attacks were divided into 2 groups: Group I, for attacks lasting > 2 hours, and Group II, for attacks lasting < 2 hours.The two groups were statistically compared using Fisher’s exact test (p < 0.05). Results In this study, 51(34%) subjects were male and 99 (66%) were female, aged 7–15 years. Fisher’s exact test demonstrated that the ICHD-3 beta had a 58% sensitivity for Group I diagnoses and a 94% sensitivity for Group II diagnoses (p < 0.001). Conclusion The current ICHD-3 beta classification improves and advances migraine diagnosis in children and adolescents; however, more research is needed to identify additional characteristics of headache in this age group.

Dihydroergotamine infusion for pediatric refractory headache: A retrospective chart review

“…1 The prevalence of pediatric primary headaches is reported to be as high as 58.4% 2 with up to 25% developing chronic recurrent headaches. 3 Previous research supports that the prevalence and clinical presentation of primary headaches vary according to patient characteristics such as age, sex, associated diagnoses, and comorbid conditions. In children, clinical presentations differ and often lack the classic features that define most adult headache syndromes.…”

“…Headaches are the most common referral to neurology practices worldwide 1 . The prevalence of pediatric primary headaches is reported to be as high as 58.4% 2 with up to 25% developing chronic recurrent headaches 3 . Previous research supports that the prevalence and clinical presentation of primary headaches vary according to patient characteristics such as age, sex, associated diagnoses, and comorbid conditions.…”

“…Most headaches (65.0%, 130/200) met the International Classification of Headache Disorders, 3rd edition criteria for migraine, followed by new daily persistent headache (25.5%, 51/200). Mean DHE maximum dose was 5.3 (SD 2.17; range 0.5-14.5 mg) with most patients requiring 3.5-6.5 mg. DHE was typically terminated at six doses (range [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]. The most frequently reported adverse event was nausea (5.5%, 11/200).…”